Mon Feb 3,12:36 PM ET
Biotechnology company Biogen Inc. said Monday it will pay $55 million to the U.S. affiliate of German drug maker Schering AG to settle a patent dispute over a drug for multiple sclerosis.
Last week, the U.S. Court of Appeals upheld most of a ruling that Biogen did not violate patents held by Schering's Berlex Laboratories Inc. on the production of beta interferon in mammalian Chinese hamster ovary cells.
Beta interferon is the active ingredient of Avonex, Biogen's best-selling drug for multiple sclerosis, a debilitating neurological disease.
The companies had earlier agreed to hold Biogen's payments to $250 million
if the appeals court ruled in Schering's favor. In January, Biogen agreed
to pay Berlex $20 million and agreed to make a second payment if it lost
Copyright © 2003 The Associated Press